Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMOEP in Untreated Peripheral T-Cell Lymphoma
NCT06433362Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in peripheral T-cell lymphoma (PTCL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jun 2024; status: recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06433362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433362.